AR090885A1 - Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple - Google Patents
Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multipleInfo
- Publication number
- AR090885A1 AR090885A1 ARP130101459A ARP130101459A AR090885A1 AR 090885 A1 AR090885 A1 AR 090885A1 AR P130101459 A ARP130101459 A AR P130101459A AR P130101459 A ARP130101459 A AR P130101459A AR 090885 A1 AR090885 A1 AR 090885A1
- Authority
- AR
- Argentina
- Prior art keywords
- human patient
- multiple sclerosis
- treatment
- presenting
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Métodos para tratar a un paciente humano afectado por esclerosis múltiple o que presenta un síndrome clínicamente aislado, métodos para tratar a un sujeto humano mediante la provisión de neuroprotección al sujeto humano, y métodos para tratar a un paciente humano afectado por esclerosis múltiple o que presenta un síndrome clínicamente aislado mediante el incremento del tiempo hasta progresión de enfermedad confirmada, el incremento del tiempo hasta recaída confirmada o la reducción de atrofia cerebral en el paciente humano, que comprende administrar oralmente al paciente humano o sujeto una dosis diaria de aproximadamente 1,2 mg de laquinimod o una sal del mismo farmacéuticamente aceptable. La presente también provee una unidad de dosificación farmacéutica oral de aproximadamente 1,2 mg de laquinimod o una sal farmacéuticamente aceptable del mismo y un vehículo farmacéuticamente aceptable para usar en el tratamiento de un paciente humano afectado por esclerosis múltiple o que presenta un síndrome clínicamente aislado, para usar en el tratamiento de un sujeto humano mediante la provisión de neuroprotección al sujeto humano, o para usar en el tratamiento de un paciente humano afectado por esclerosis múltiple o que presenta un síndrome clínicamente aislado mediante el incremento del tiempo hasta progresión de enfermedad confirmada, el incremento del tiempo hasta recaída confirmada o la reducción de atrofia cerebral en el paciente humano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641389P | 2012-05-02 | 2012-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090885A1 true AR090885A1 (es) | 2014-12-10 |
Family
ID=49514859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101459A AR090885A1 (es) | 2012-05-02 | 2013-04-29 | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20130303569A1 (es) |
| EP (1) | EP2844255A4 (es) |
| JP (2) | JP2015515985A (es) |
| KR (1) | KR20150013658A (es) |
| CN (2) | CN105832733A (es) |
| AR (1) | AR090885A1 (es) |
| AU (1) | AU2013256352A1 (es) |
| BR (1) | BR112014027010A2 (es) |
| CA (1) | CA2870684A1 (es) |
| CL (1) | CL2014002935A1 (es) |
| EA (1) | EA201492010A1 (es) |
| HK (1) | HK1206246A1 (es) |
| IL (1) | IL235337A0 (es) |
| MX (1) | MX2014013039A (es) |
| PE (1) | PE20150161A1 (es) |
| PH (1) | PH12014502447A1 (es) |
| SG (1) | SG11201406594UA (es) |
| TW (2) | TW201347762A (es) |
| UY (1) | UY34775A (es) |
| WO (1) | WO2013166166A1 (es) |
| ZA (1) | ZA201408820B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889627B2 (en) | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| US9284276B2 (en) | 2012-02-16 | 2016-03-15 | Teva Pharmaceutical Industries, Ltd. | N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| EP2961406A4 (en) * | 2012-10-12 | 2017-01-04 | Teva Pharmaceutical Industries Ltd. | Laquinimod for reducing thalamic damage in multiple sclerosis |
| MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
| AU2014216199A1 (en) * | 2013-02-15 | 2015-09-03 | Teva Pharmaceutical Industries Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
| NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| AR098924A1 (es) * | 2013-12-23 | 2016-06-22 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida |
| AU2015253330A1 (en) * | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
| WO2017027512A1 (en) * | 2015-08-13 | 2017-02-16 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to treat traumatic brain injury |
| US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
| TW202019425A (zh) * | 2018-07-20 | 2020-06-01 | 德商馬克專利公司 | 利用經取代胺基-嘧啶化合物治療及預防多發性硬化症之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| PL1797109T3 (pl) * | 2004-09-09 | 2016-11-30 | Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania | |
| WO2007146331A1 (en) * | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| NZ597378A (en) * | 2009-06-19 | 2014-08-29 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| WO2011086470A1 (en) * | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Treatment of multiple sclerosis |
| US8889627B2 (en) * | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| AU2014216199A1 (en) * | 2013-02-15 | 2015-09-03 | Teva Pharmaceutical Industries Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
-
2013
- 2013-04-29 TW TW102115308A patent/TW201347762A/zh unknown
- 2013-04-29 TW TW106117959A patent/TW201804997A/zh unknown
- 2013-04-29 AR ARP130101459A patent/AR090885A1/es unknown
- 2013-04-30 UY UY0001034775A patent/UY34775A/es not_active Application Discontinuation
- 2013-05-01 JP JP2015510436A patent/JP2015515985A/ja not_active Withdrawn
- 2013-05-01 MX MX2014013039A patent/MX2014013039A/es unknown
- 2013-05-01 EA EA201492010A patent/EA201492010A1/ru unknown
- 2013-05-01 KR KR1020147033707A patent/KR20150013658A/ko not_active Application Discontinuation
- 2013-05-01 SG SG11201406594UA patent/SG11201406594UA/en unknown
- 2013-05-01 CN CN201610240473.8A patent/CN105832733A/zh active Pending
- 2013-05-01 PE PE2014001911A patent/PE20150161A1/es not_active Application Discontinuation
- 2013-05-01 WO PCT/US2013/039090 patent/WO2013166166A1/en active Application Filing
- 2013-05-01 BR BR112014027010A patent/BR112014027010A2/pt not_active IP Right Cessation
- 2013-05-01 EP EP13784231.6A patent/EP2844255A4/en not_active Withdrawn
- 2013-05-01 US US13/874,537 patent/US20130303569A1/en not_active Abandoned
- 2013-05-01 CA CA2870684A patent/CA2870684A1/en not_active Abandoned
- 2013-05-01 AU AU2013256352A patent/AU2013256352A1/en not_active Abandoned
- 2013-05-01 CN CN201380022530.XA patent/CN104284663A/zh active Pending
-
2014
- 2014-10-26 IL IL235337A patent/IL235337A0/en unknown
- 2014-10-29 CL CL2014002935A patent/CL2014002935A1/es unknown
- 2014-10-31 PH PH12014502447A patent/PH12014502447A1/en unknown
- 2014-12-02 ZA ZA2014/08820A patent/ZA201408820B/en unknown
-
2015
- 2015-06-05 US US14/731,971 patent/US20150265592A1/en not_active Abandoned
- 2015-07-16 HK HK15106789.5A patent/HK1206246A1/xx unknown
- 2015-09-15 US US14/854,849 patent/US20160000775A1/en not_active Abandoned
-
2017
- 2017-07-21 JP JP2017141409A patent/JP2017222691A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017222691A (ja) | 2017-12-21 |
| BR112014027010A2 (pt) | 2017-06-27 |
| EP2844255A1 (en) | 2015-03-11 |
| KR20150013658A (ko) | 2015-02-05 |
| CN104284663A (zh) | 2015-01-14 |
| JP2015515985A (ja) | 2015-06-04 |
| PE20150161A1 (es) | 2015-02-22 |
| US20150265592A1 (en) | 2015-09-24 |
| MX2014013039A (es) | 2015-02-04 |
| TW201347762A (zh) | 2013-12-01 |
| PH12014502447A1 (en) | 2015-01-12 |
| SG11201406594UA (en) | 2014-11-27 |
| EP2844255A4 (en) | 2015-10-14 |
| WO2013166166A1 (en) | 2013-11-07 |
| UY34775A (es) | 2013-11-29 |
| EA201492010A1 (ru) | 2015-06-30 |
| IL235337A0 (en) | 2014-12-31 |
| HK1206246A1 (en) | 2016-01-08 |
| CN105832733A (zh) | 2016-08-10 |
| AU2013256352A1 (en) | 2014-11-27 |
| TW201804997A (zh) | 2018-02-16 |
| US20160000775A1 (en) | 2016-01-07 |
| US20130303569A1 (en) | 2013-11-14 |
| CL2014002935A1 (es) | 2015-03-06 |
| ZA201408820B (en) | 2016-06-29 |
| CA2870684A1 (en) | 2013-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| NZ597378A (en) | Treatment of multiple sclerosis with laquinimod | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| JP2013155188A5 (es) | ||
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| JP2013541583A5 (es) | ||
| AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| GT200600263A (es) | Regimen de dosificacion para prasugrel | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| BR112014004339A2 (pt) | suspensão oral | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| MX2010006310A (es) | O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| AR114012A1 (es) | Método para proporcionar terapia de celiprolol a un paciente |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |